Basic Information
| LncRNA/CircRNA Name | SAMMSON |
| Synonyms | NA |
| Region | GRCh38_3:69999550-70518064 |
| Ensemble | ENSG00000240405 |
| Refseq | NR_110000 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioblastoma |
| ICD-0-3 | NA |
| Methods | qPCR |
| Sample | U87 (ATCC, USA) and U-373 MG human GBM cell lines, blood |
| Expression Pattern | up-regulated |
| Function Description | lncRNA Survival Associated Mitochondrial Melanoma-Specific Oncogenic NonCoding RNA (SAMMSON) was upregulated in plasma of glioblastoma patients but not in diffuse neurosarcoidosis patients comparing to healthy controls. Upregulated SAMMSON distinguished glioblastoma patients from diffuse neurosarcoidosis patients and healthy controls. MiR-622 in glioblastoma patients was inversely correlated with SAMMSON. SAMMSON overexpression caused the downregulated expression of miR-622 in glioblastoma cells, while miR-622 overexpression did not affect SAMMSON expression. SAMMSON overexpression mediated the increased proliferation rate of glioblastoma cells. MiR-622 overexpression played an opposite role and reduced the effects of SAMMSON overexpression. |
| Pubmed ID | 31283714 |
| Year | 2019 |
| Title | LncRNA SAMMSON overexpression distinguished glioblastoma patients from patients with diffuse neurosarcoidosis |
External Links
| Links for SAMMSON | GenBank HGNC NONCODE |
| Links for glioblastoma | OMIM COSMIC |